Trials / Completed
CompletedNCT06571266
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | • Subcutaneous Injection via prefilled syringe |
Timeline
- Start date
- 2024-09-11
- Primary completion
- 2025-04-16
- Completion
- 2025-04-16
- First posted
- 2024-08-26
- Last updated
- 2025-05-16
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06571266. Inclusion in this directory is not an endorsement.